Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical company developing ribonucleic acid-modulating drug candidates, each designed to be a eukaryotic ribosomal selective glycoside (ERSG), formulated to treat premature stop codon disorders. ELX-02, Co.'s primary investigational drug product candidate, is a small molecule designed to restore production of functional proteins. ELX-02 is in clinical development for systemic administration for cystic fibrosis and nephropathic cystinosis. Co. has a program studying ERSG compounds for autosomal dominant polycystic kidney disease and in rare inherited retinal disorders by intravitreal administration with an initial focus on Usher Syndrome. The ELOX stock yearly return is shown above.
The yearly return on the ELOX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2019 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ELOX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|